

TRANSLATION

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

| | | |
|--|--|--|
| Applicant's or agent's file reference FLAMEL 0090 | FOR FURTHER ACTION | See Form PCT/IPEA/416 |
| International application No. PCT/FR2004/050605 | International filing date (<i>day/month/year</i>) 19.11.2004 | Priority date (<i>day/month/year</i>) 21.11.2003 |
| International Patent Classification (IPC) or national classification and IPC A61K38/21, A61K9/10, A61P35/00, A61K47/48 | | |
| Applicant FLAMEL TECHNOLOGIES | | |

| |
|---|
| 1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36. |
| 2. This REPORT consists of a total of <u>7</u> sheets, including this cover sheet. |
| 3. This report is also accompanied by ANNEXES, comprising: a. <input checked="" type="checkbox"/> (<i>sent to the applicant and to the International Bureau</i>) a total of <u>7</u> sheets, as follows: <input checked="" type="checkbox"/> sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions). <input type="checkbox"/> sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box. b. <input type="checkbox"/> (<i>sent to the International Bureau only</i>) a total of (indicate type and number of electronic carrier(s)) _____, containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions). |
| 4. This report contains indications relating to the following items: <input checked="" type="checkbox"/> Box No. I Basis of the report <input type="checkbox"/> Box No. II Priority <input type="checkbox"/> Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability <input type="checkbox"/> Box No. IV Lack of unity of invention <input checked="" type="checkbox"/> Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement <input checked="" type="checkbox"/> Box No. VI Certain documents cited <input type="checkbox"/> Box No. VII Certain defects in the international application <input type="checkbox"/> Box No. VIII Certain observations on the international application |

| | |
|---|-----------------------------------|
| Date of submission of the demand | Date of completion of this report |
| Name and mailing address of the IPEA/EP | Authorized officer |
| Facsimile No. | Telephone No. |

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/FR2004/050605

Box No. I Basis of the report

1. With regard to the **language**, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.
- ☐ This report is based on translations from the original language into the following language _____, which is the language of a translation furnished for the purposes of:
- ☐ international search (Rule 12.3 and 23.1(b))
- ☐ publication of the international application (Rule 12.4)
- ☐ international preliminary examination (Rule 55.2 and/or 55.3)
2. With regard to the **elements** of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report)*:
- ☐ the international application as originally filed/furnished
- ☒ the description:
- pages 1-9, 11-16, 18-31 as originally filed/furnished
- pages* 10, 17 received by this Authority on 28.09.2005 with letter of 21.09.2005
- pages* _____ received by this Authority on _____
- ☒ the claims:
- nos. 7 (in part), 8 (in part), 25-34 as originally filed/furnished
- nos.* _____ as amended (together with any statement) under Article 19
- nos.* 1-6, 7 (in part), 8 (in part), 9-24 received by this Authority on 28.09.2005 with letter of 21.09.2005
- nos.* _____ received by this Authority on _____
- ☒ the drawings:
- sheets 1/1 as originally filed/furnished
- sheets* _____ received by this Authority on _____
- sheets* _____ received by this Authority on _____
- ☐ a sequence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing.
3. ☐ The amendments have resulted in the cancellation of:
- ☐ the description, pages _____
- ☐ the claims, nos. _____
- ☐ the drawings, sheets/figs _____
- ☐ the sequence listing (*specify*): _____
- ☐ any table(s) related to sequence listing (*specify*): _____
4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).
- ☐ the description, pages _____
- ☐ the claims, nos. _____
- ☐ the drawings, sheets/figs _____
- ☐ the sequence listing (*specify*): _____
- ☐ any table(s) related to sequence listing (*specify*): _____

* If item 4 applies, some or all of those sheets may be marked "superseded."

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/FR2004/050605

| Box No. V | Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement | | |
|-----------|--|-------------------------------------|-----|
| 1. | Statement | | |
| | Novelty (N) | Claims <u>10-11, 17-20, 22-23</u> | YES |
| | | Claims <u>1-9, 12-16, 21, 24-34</u> | NO |
| | Inventive step (IS) | Claims _____ | YES |
| | | Claims <u>1-34</u> | NO |
| | Industrial applicability (IA) | Claims <u>1-34</u> | YES |
| | | Claims _____ | NO |
| 2. | Citations and explanations (Rule 70.7) | | |
| | Reference is made to the following documents: | | |
| | D1: FR-A-2 786 098 | | |
| | D2: FR-A-2 732 218 | | |
| | D3: FR-A-2 801 226 | | |
| | D4: FR-A-2 822 834 | | |
| | D5: FR-A-2 838 964 | | |
| | D6: WO 99/18142 A | | |
| | Unless otherwise indicated, reference is also made to the relevant passages cited in the international search report for said documents. | | |
| | 2.1 | | |
| | D1 to D5 all describe colloidal suspensions of submicronic particles vectoring interferon, based on polymers that are biodegradable, water-soluble and have hydrophobic groups. Said formulations form spontaneously by dispersal in water and enable the sustained release of interferon after parenteral administration. | | |
| | In D1, poly(Glu) or poly(Asp) polymers are used and one example describes the controlled release of insulin for up to 20 hours. Hence, claims 1, 6 to 9, 12 to 16, 21 and 24 to 34 are not novel over D1 (PCT Article 33(2)). | | |

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/FR2004/050605

| Box No. V | Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement |
|-----------|--|
| | <p>In D2-D4, the polymers used contain a first type of monomer consisting of Glu and/or Asp amino acids and a second type of hydrophobic monomer consisting of Leu, Ile, Ala, Val, Pro and Phe amino acids. Hence, claims 1, 6 to 9, 12 to 16, 21 and 24 to 34 are not novel over D2-D4 (PCT Article 33(2)). D3 and D4 describe examples of controlled release of insulin for up to 24 and 30 hours respectively.</p> <p>In D5, the polymers used are arrangements of Glu and/or Asp polyamino acids with hydrophobic polymers, preferably lactic acid or glycolic acid polymers. Controlled release of insulin for up to 12 hours is also described. Hence, claims 1, 6 to 8, 12 to 16, 21 and 24 to 34 are not novel over D5 (PCT Article 33(2)).</p> <p>In D6, the polymers are triblock polymers that have hydrophobic groups. After injection into the human body, said polymers spontaneously form a gelled deposit. The formation of said deposit is dependent on the temperature to which the polymer is subjected, but is not pH-dependent (page 28, lines 4 and 5). Hence, claims 1 to 3, 16 and 24 to 34 are not novel over D6 (PCT Article 33(2)).</p> <p>None of the prior art documents measures the concentration of the polymer according to the "induced gelling" concentration (CI) and discloses the viscosity of the formulations obtained. However, claims 4 and 5 are not considered novel given that the formulations of claim 1 are not novel over D1 to D6. The difference between the subject matter of the present application and that of the prior art is not clear and it appears that the formulations of the prior art also come within the definition of claims 4 and 5 (PCT Article 33(2)). Since the formulations of the prior art come within the definition of the formulations of claim 1, they must implicitly form a gelled deposit <i>in vivo</i> and enable controlled release of an active agent (as in fact indicated in D1 and D3 to D5 with regard to insulin).</p> <p>Indeed, claim 1 discloses no technical feature that would enable the formulations of the present application to be differentiated</p> |

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/FR2004/050605

Box No. V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
citations and explanations supporting such statement

from those of the prior art. Claim 1 appears to lack an essential feature that would enable such differentiation (PCT Articles 5 and 6). The [PO] concentration appears to be the feature that would enable the formulations of the present application to be differentiated from the prior art, in that, in the presence of a physiological protein, they form a gelled deposit enabling controlled release of interferon over more than 24 hours.

Hence, only claims 10 to 11, 17 to 20 and 22 to 23 appear novel over D1 to D6 (PCT Article 33(2)).

2.2

The formulations of claims 10 to 11 and 17 to 20 do not involve an inventive step, since they correspond to alternatives that do not have unexpected effects or properties relative to those of the prior art.

The same applies to claims 22 and 23 (PCT Article 33(3)).

As mentioned above, the technical features whereby the subject matter of the present application may be differentiated from that of the prior art appear neither in the claims nor in the description.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/FR2004/050605

Box No. VI

Certain documents cited

1. Certain published documents (Rule 70.10)

| Application No. Patent No. | Publication date (day/month/year) | Filing date (day/month/year) | Priority date (valid claim) (day/month/year) |
|-------------------------------|--------------------------------------|---------------------------------|---|
| WO03/104303 (D7) | 18.12.2003 | 03.06.2003 | 07.06.2002 |
| WO2004/013206 (D8) | 12.02.2004 | 23.07.2003 | 30.07.2002 |

2. Non-written disclosures (Rule 70.9)

| Kind of non-written disclosure | Date of non-written disclosure (day/month/year) | Date of written disclosure referring to non-written disclosure (day/month/year) |
|--------------------------------|--|---|
|--------------------------------|--|---|

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of: **Box VI**

D7 describes (Glu and/or Asp) polyaminoacids functionalised by alpha-tocopherol and useful for vectoring interferon. The formulations are capable of forming a gelled deposit *in vivo*.

D8 also describes (Glu and/or Asp) polyaminoacids functionalised by hydrophobic groups and useful for vectoring interferon. The formulations are capable of forming a gelled deposit *in vivo*.